MedTrace Logo

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon

NCT02486640 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2023-07-24

No results posted yet for this study

Summary

This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon

Conditions

Interventions

DRUG

Interferon beta-1b (Betaferon, BAY86-5046)

Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.

DEVICE

Betaconnect Autoinjector

Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-08
Primary Completion
2019-10-31
Completion
2020-01-16

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02486640 on ClinicalTrials.gov